Diagnostic Tests and Biomarkers for Pheochromocytoma and Extra-adrenal Paraganglioma: From Routine Laboratory Methods to Disease Stratification
Tóm tắt
Từ khóa
Tài liệu tham khảo
Eisenhofer G, Goldstein DS, Kopin IJ, Crout JR: Pheochromocytoma: rediscovery as a catecholamine-metabolizing tumor. Endocr Pathol 14:193–212, 2003
Eisenhofer G, Kopin IJ, Goldstein DS: Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 56:331–49, 2004
Eisenhofer G, Lenders JW, Linehan WM, Walther MM, Goldstein DS, Keiser HR: Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel–Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 340:1872–9, 1999
Lenders JW, Pacak K, Walther MM, et al.: Biochemical diagnosis of pheochromocytoma: which test is best? Jama 287:1427–34, 2002
Pacak K, Eisenhofer G, Ahlman H, et al.: Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat Clin Pract Endocrinol Metab 3:92–102, 2007
Raber W, Raffesberg W, Bischof M, et al.: Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Arch Intern Med 160:2957–63, 2000
Sawka AM, Jaeschke R, Singh RJ, Young WF, Jr.: A comparison of biochemical tests for pheochromocytoma: Measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 88:553–8, 2003
Unger N, Pitt C, Schmidt IL, et al.: Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur J Endocrinol 154:409–17, 2006
Vaclavik J, Stejskal D, Lacnak B, et al.: Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients. J Hypertens 25:1427–31, 2007
Hickman PE, Leong M, Chang J, Wilson SR, McWhinney B: Plasma free metanephrines are superior to urine and plasma catecholamines and urine catecholamine metabolites for the investigation of phaeochromocytoma. Pathology 41:173–7, 2009
Gao YC, Lu HK, Luo QY, Chen LB, Ding Y, Zhu RS: Comparison of free plasma metanephrines enzyme immunoassay with (131)I-MIBG scan in diagnosis of pheochromocytoma. Clin Exp Med 8:87–91, 2008
Sarathi V, Pandit R, Jagtap V, et al.: Performance of fractionated plasma free metanephrines by enzyme immunoassay in the diagnosis of pheochromocytoma and paraganglioma. Endocr Pract 17:759–65, 2011
Marney LC, Laha TJ, Baird GS, Rainey PM, Hoofnagle AN: Isopropanol protein precipitation for the analysis of plasma free metanephrines by liquid chromatography-tandem mass spectrometry. Clin Chem 54:1729–32, 2008
Whiting MJ: Simultaneous measurement of urinary metanephrines and catecholamines by liquid chromatography with tandem mass spectrometric detection. Ann Clin Biochem 46:129–36, 2009
Peaston RT, Graham KS, Chambers E, van der Molen JC, Ball S: Performance of plasma free metanephrines measured by liquid chromatography-tandem mass spectrometry in the diagnosis of pheochromocytoma. Clin Chim Acta 411:546–52, 2010
Marrington R, Johnston J, Knowles S, Webster C: Measurement of urinary metadrenaline and normetadrenaline by liquid chromatography tandem mass spectrometry for the diagnosis of phaeochromocytoma. Ann Clin Biochem 47:467–75, 2010
Gabler J, Miller A, Wang S: A simple liquid chromatography-tandem mass spectrometry method for measuring metanephrine and normetanephrine in urine. Clin Chem Lab Med 49:1213–6, 2011
He X, Gabler J, Yuan C, Wang S, Shi Y, Kozak M: Quantitative measurement of plasma free metanephrines by ion-pairing solid phase extraction and liquid chromatography-tandem mass spectrometry with porous graphitic carbon column. J Chromatogr B Analyt Technol Biomed Life Sci 879:2355–9, 2011
Pillai D, Ross HA, Kratzsch J, et al.: Proficiency test of plasma free and total metanephrines: report from a study group. Clin Chem Lab Med 47:786–90, 2009
Pillai D, Callen S: Pilot quality assurance programme for plasma metanephrines. Ann Clin Biochem 47:137–42, 2010
Mullins F, O’Shea P, Fitzgerald R, Tormey W: Enzyme-linked immunoassay for plasma-free metanephrines in the biochemical diagnosis of phaeochromocytoma in adults is not ideal. Clin Chem Lab Med 2011 (in press)
Boyle JG, Davidson DF, Perry CG, Connell JM: Comparison of diagnostic accuracy of urinary free metanephrines VMA, and catecholamines and plasma catecholamines for diagnosis of pheochromocytoma. J Clin Endocrinol Metab 92:4602–8, 2007
Douwes Dekker PB, Corver WE, Hogendoorn PC, van der Mey AG, Cornelisse CJ: Multiparameter DNA flow-sorting demonstrates diploidy and SDHD wild-type gene retention in the sustentacular cell compartment of head and neck paragangliomas: chief cells are the only neoplastic component. J Pathol 202:456–62, 2004
Linnoila RI, Keiser HR, Steinberg SM, Lack EE: Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol 21:1168–80, 1990
Kimura N, Watanabe T, Noshiro T, Shizawa S, Miura Y: Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol 16:23–32, 2005
Thompson LD: Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 26:551–66, 2002
Gao B, Meng F, Bian W, et al.: Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomas. Urology 68:282–6, 2006
Strong VE, Kennedy T, Al-Ahmadie H, et al.: Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery 143:759–68, 2008
Wu D, Tischler AS, Lloyd RV, et al.: Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score. Am J Surg Pathol 33:599–608, 2009
Agarwal A, Mehrotra PK, Jain M, et al.: Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy? World J Surg 34:3022–8, 2010
Favier J, Plouin PF, Corvol P, Gasc JM: Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am J Pathol 161:1235–46, 2002
Eisenhofer G, Lenders JW, Siegert G, et al.: Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumor size, location and SDHB mutation status. Eur J Cancer 2011 (in press)
Remine W, Chong G, van Heerden J, Sheps S, Harrison EJ: Current management of pheochromocytoma. Ann Surg 179:740–8, 1974
Shen WT, Sturgeon C, Clark OH, Duh QY, Kebebew E: Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas. Surgery 136:1129–37, 2004
van der Harst E, Bruining HA, Jaap Bonjer H, et al.: Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases? J Pathol 191:175–80, 2000
Ayala-Ramirez M, Feng L, Johnson MM, et al.: Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab 96:717–25, 2011
Feng F, Zhu Y, Wang X, et al.: Predictive factors for malignant pheochromocytoma: analysis of 136 patients. J Urol 185:1583–90, 2011
John H, Ziegler WH, Hauri D, Jaeger P: Pheochromocytomas: can malignant potential be predicted? Urology 53:679–83, 1999
Park J, Song C, Park M, et al.: Predictive characteristics of malignant pheochromocytoma. Korean J Urol 52:241–6, 2011
Clarke MR, Weyant RJ, Watson CG, Carty SE: Prognostic markers in pheochromocytoma. Hum Pathol 29:522–6, 1998
Medeiros LJ, Wolf BC, Balogh K, Federman M: Adrenal pheochromocytoma: a clinicopathologic review of 60 cases. Hum Pathol 16:580–9, 1985
Plouin PF, Chatellier G, Fofol I, Corvol P: Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension 29:1133–9, 1997
Proye C, Vix M, Goropoulos A, Kerlo P, Lecomte-Houcke M: High incidence of malignant pheochromocytoma in a surgical unit. 26 cases out of 100 patients operated from 1971 to 1991. J Endocrinol Invest 15:651–63, 1992
Goldstein RE, O’Neill JA, Jr., Holcomb GW, 3rd, et al.: Clinical experience over 48 years with pheochromocytoma. Ann Surg 229:755–64; discussion 64–6, 1999
Mannelli M, Ianni L, Cilotti A, Conti A: Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol 141:619–24, 1999
Edstrom Elder E, Hjelm Skog AL, Hoog A, Hamberger B: The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol 29:278–83, 2003
Amar L, Servais A, Gimenez-Roqueplo AP, Zinzindohoue F, Chatellier G, Plouin PF: Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 90:2110–6, 2005
Chapman DB, Lippert D, Geer CP, et al.: Clinical, histopathologic, and radiographic indicators of malignancy in head and neck paragangliomas. Otolaryngol Head Neck Surg 143:531–7, 2010
Ghayee HK, Havekes B, Corssmit EP, et al.: Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior. Endocr Relat Cancer 16:291–9, 2009
Amar L, Bertherat J, Baudin E, et al.: Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 23:8812–8, 2005
Brouwers FM, Eisenhofer G, Tao JJ, et al.: High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab 91:4505–9, 2006
Ricketts CJ, Forman JR, Rattenberry E, et al.: Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat 31:41–51, 2010
King KS, Prodanov T, Kantorovich V, et al.: Metastatic Pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol 29:4137–42, 2011
Eisenhofer G, Huynh TT, Pacak K, et al.: Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel–Lindau syndrome. Endocrine-Related Cancer 11:897–911, 2004
Dahia PL, Ross KN, Wright ME, et al.: A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 1:72–80, 2005
Favier J, Briere JJ, Burnichon N, et al.: The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS One 4:e7094, 2009
Lopez-Jimenez E, Gomez-Lopez G, Leandro-Garcia LJ, et al.: Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol 24:2382–91, 2010
Burnichon N, Vescovo L, Amar L, et al.: Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet 20:3974–3985, 2011
Eisenhofer G, Lenders JW, Timmers H, et al.: Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem 57:411–20, 2011
Eisenhofer G, Pacak K, Huynh TT, et al.: Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr Relat Cancer 18:97–111, 2011
Eisenhofer G, Timmers H, Lenders JW, et al.: Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location. Journal of Clinical Endocrinology and Metabolism 96:375–84, 2011
Robinson R, Smith P, Whittaker SR: Secretion of catecholamines in malignant phaeochromocytoma. Br Med J 1:1422–4, 1964
Tippett PA, McEwan AJ, Ackery DM: A re-evaluation of dopamine excretion in phaeochromocytoma. Clin Endocrinol (Oxf) 25:401–10, 1986
Rao F, Keiser HR, O’Connor DT: Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment. Hypertension 36:1045–52, 2000
Januszewicz W, Wocial B, Januszewicz A, Gryglas P, Prejbisz A: Dopamine and dopa urinary excretion in patients with pheochromocytoma—diagnostic implications. Blood Press 10:212–6, 2001
van der Harst E, de Herder WW, de Krijger RR, et al.: The value of plasma markers for the clinical behaviour of phaeochromocytomas. Eur J Endocrinol 147:85–94, 2002
Yon L, Guillemot J, Montero-Hadjadje M, et al.: Identification of the secretogranin II-derived peptide EM66 in pheochromocytomas as a potential marker for discriminating benign versus malignant tumors. J Clin Endocrinol Metab 88:2579–85, 2003
Guerin M, Guillemot J, Thouennon E, et al.: Granins and their derived peptides in normal and tumoral chromaffin tissue: implications for the diagnosis and prognosis of pheochromocytoma. Regul Pept 165:21–9, 2010
Szalat A, Fraenkel M, Doviner V, Salmon A, Gross DJ: Malignant pheochromocytoma: predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center. Endocrine 39:160–6, 2011
Timmers HJ, Pacak K, Huynh TT, et al.: Biochemically silent abdominal paragangliomas in patients with mutations in the Sdhb Gene. J Clin Endocrinol Metab 93:4826–4832, 2008
Eisenhofer G, Lenders JW, Goldstein DS, et al.: Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem 51:735–44, 2005
van Nederveen FH, Gaal J, Favier J, et al.: An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 10:764–71, 2009
Korpershoek E, Favier J, Gaal J, et al.: SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab 96:E1472–6, 2011
Gill AJ, Benn DE, Chou A, et al.: Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma–pheochromocytoma syndromes. Hum Pathol 41:805–14, 2010
Gill AJ, Chou A, Vilain R, et al.: Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types. Am J Surg Pathol 34:636–44, 2011
Gaal J, Stratakis CA, Carney JA, et al.: SDHB immunohistochemistry: a useful tool in the diagnosis of Carney–Stratakis and Carney triad gastrointestinal stromal tumors. Mod Pathol 24:147–51, 2011
Janeway KA, Kim SY, Lodish M, et al.: Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A 108:314–8, 2011
Miettinen M, Wang ZF, Sarlomo-Rikala M, Osuch C, Rutkowski P, Lasota J: Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol 35:1712–21, 2011
Gill AJ, Chou A, Vilain RE, Clifton-Bligh RJ: “Pediatric-type” gastrointestinal stromal tumors are SDHB negative (“type 2”) GISTs. Am J Surg Pathol 35:1245–7; author reply 7–8, 2011
Gill AJ, Pachter NS, Clarkson A, et al.: Renal tumors and hereditary pheochromocytoma-paraganglioma syndrome type 4. N Engl J Med 364:885–6, 2011
Gill AJ, Pachter NS, Chou A, et al.: Renal tumors associated with germline SDHB mutation show distinctive morphology. Am J Surg Pathol 35:1578–85, 2011
Sandgren J, Andersson R, Rada-Iglesias A, et al.: Integrative epigenomic and genomic analysis of malignant pheochromocytoma. Exp Mol Med 42:484–502, 2010
Brouwers FM, Petricoin EF, 3rd, Ksinantova L, et al.: Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. Endocr Relat Cancer 12:263–72, 2005
Brouwers FM, Elkahloun AG, Munson PJ, et al.: Gene expression profiling of benign and malignant pheochromocytoma. Ann N Y Acad Sci 1073:541–56, 2006
Suh I, Shibru D, Eisenhofer G, et al.: Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling. Ann Surg 250:983–90, 2009
Bjorklund P, Cupisti K, Fryknas M, et al.: Stathmin as a marker for malignancy in pheochromocytomas. Exp Clin Endocrinol Diabetes 118:27–30, 2010
Thouennon E, Pierre A, Tanguy Y, et al.: Expression of trophic amidated peptides and their receptors in benign and malignant pheochromocytomas: high expression of adrenomedullin RDC1 receptor and implication in tumoral cell survival. Endocr Relat Cancer 17:637–51, 2010
Waldmann J, Fendrich V, Holler J, et al.: Microarray analysis reveals differential expression of benign and malignant pheochromocytoma. Endocr Relat Cancer 17:743–56, 2010
Thouennon E, Elkahloun AG, Guillemot J, et al.: Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy. J Clin Endocrinol Metab 92:4865–72, 2007
Eisenhofer G, Bornstein SR, Brouwers FM, et al.: Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 11:423–36, 2004
Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB: The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 14:569–85, 2007
Tombol Z, Eder K, Kovacs A, et al.: MicroRNA expression profiling in benign (sporadic and hereditary) and recurring adrenal pheochromocytomas. Mod Pathol 23:1583–95, 2010
Meyer-Rochow GY, Jackson NE, Conaglen JV, et al.: MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocr Relat Cancer 17:835–46, 2010
Grossman A, Pacak K, Sawka A, et al.: Biochemical diagnosis and localization of pheochromocytoma: can we reach a consensus? Ann N Y Acad Sci 1073:332–47, 2006
Michaud GY: The role of standards in the development and implementation of clinical laboratory tests: a domestic and global perspective. Cancer Biomark 1:209–16, 2005
Hall JA, Brown R, Paul J: An exploration into study design for biomarker identification: issues and recommendations. Cancer Genomics Proteomics 4:111–9, 2007